ZA954796B - Diamines - Google Patents

Diamines

Info

Publication number
ZA954796B
ZA954796B ZA954796A ZA954796A ZA954796B ZA 954796 B ZA954796 B ZA 954796B ZA 954796 A ZA954796 A ZA 954796A ZA 954796 A ZA954796 A ZA 954796A ZA 954796 B ZA954796 B ZA 954796B
Authority
ZA
South Africa
Prior art keywords
diyl
pct
phenylene
cyclohexane
signifies
Prior art date
Application number
ZA954796A
Other languages
English (en)
Inventor
Werner Hofheinz
Werner Leupin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA954796B publication Critical patent/ZA954796B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA954796A 1994-06-17 1995-06-09 Diamines ZA954796B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH192894 1994-06-17

Publications (1)

Publication Number Publication Date
ZA954796B true ZA954796B (en) 1996-01-03

Family

ID=4221871

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA954796A ZA954796B (en) 1994-06-17 1995-06-09 Diamines

Country Status (17)

Country Link
US (1) US5736557A (xx)
EP (1) EP0765313B1 (xx)
JP (1) JPH10501540A (xx)
CN (1) CN1120156C (xx)
AT (1) ATE247642T1 (xx)
AU (1) AU691306B2 (xx)
CA (1) CA2192203A1 (xx)
DE (1) DE69531543T2 (xx)
DK (1) DK0765313T3 (xx)
ES (1) ES2204956T3 (xx)
IL (1) IL114099A (xx)
MX (1) MX9606382A (xx)
MY (1) MY115176A (xx)
NZ (1) NZ288223A (xx)
PT (1) PT765313E (xx)
WO (1) WO1995035287A1 (xx)
ZA (1) ZA954796B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100263802B1 (ko) * 1995-11-16 2001-01-15 프리돌린 클라우스너, 롤란드 비. 보레르 항말라리아성 퀴놀린 유도체
US5866562A (en) * 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
US6174897B1 (en) 1996-10-25 2001-01-16 Bayer Aktiengesellschaft Bis-(quinolyl)-diamines
US5882996A (en) * 1997-10-14 1999-03-16 Industrial Technology Research Institute Method of self-aligned dual damascene patterning using developer soluble arc interstitial layer
AU6051800A (en) * 1999-06-16 2001-01-02 University Of Iowa Research Foundation, The Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
KR100520168B1 (ko) * 1999-06-21 2005-10-10 주식회사 하이닉스반도체 화학증폭형 레지스트에 첨가되는 새로운 페닐렌디아민계 유도체
DE10008522A1 (de) * 2000-02-24 2001-09-06 Hassan Jomaa Verwendung von 2-PHenylendiaminderivaten zur Behandlung von Infektionen
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US6818772B2 (en) * 2002-02-22 2004-11-16 Abbott Laboratories Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
WO2003070244A1 (en) * 2002-02-22 2003-08-28 Abbott Laboratories Antagonist of melanin concentrating hormone and their uses
WO2007056580A2 (en) * 2005-11-08 2007-05-18 Pharmadyn, Inc. Methods and compositions for treating diseases associated with pathogenic proteins
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
US20110045100A1 (en) * 2008-03-05 2011-02-24 Georgetown University Antimalarial Quinolines and Methods of Use Thereof
WO2010059633A2 (en) * 2008-11-18 2010-05-27 Oregon Health & Science University Compounds for treating parasitic disease
CA2772085A1 (en) 2009-08-27 2011-03-03 The U.S.A., As Represented By The Secretary, Dept. Of Health And Human S Ervices Compounds that treat malaria and prevent malaria transmission
EP2394982A1 (en) 2010-06-08 2011-12-14 Lonza Ltd. Process for the preparation of cis-diaminocycloalkanes
EP2394981A1 (en) 2010-06-08 2011-12-14 Lonza Ltd. Process for the preparation of cis-diaminocycloalkanes
CN104788523B (zh) 2010-06-22 2017-09-08 欧恩科斯欧公司 用于核酸结合物的具有内涵体溶解剂的优化的体内递送系统
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
WO2015133280A1 (ja) * 2014-03-03 2015-09-11 公立大学法人名古屋市立大学 抗マラリア活性化合物及び抗マラリア薬
CN107001237B (zh) * 2014-11-25 2019-11-19 巴斯夫欧洲公司 制备顺式和反式富集的mdach的方法
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
JP6342088B2 (ja) * 2016-06-28 2018-06-13 大日本印刷株式会社 化合物、及びその中間体
EP3565577A4 (en) 2017-01-06 2020-10-07 Avidity Biosciences, Inc. NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCTION OF EXON SKIP
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
JP2021500862A (ja) 2017-10-04 2021-01-14 アビディティー バイオサイエンシーズ，インク． 核酸ポリペプチド組成物およびその使用
KR102623786B1 (ko) 2017-12-06 2024-01-11 어비디티 바이오사이언시스 인크. 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
AU2019406199A1 (en) 2018-12-21 2021-07-29 Avidity Biosciences, Inc. Anti-transferrin receptor antibodies and uses thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
US12006499B2 (en) 2019-06-06 2024-06-11 Avidity Biosciences, Inc. Una amidites and uses thereof
US11578090B2 (en) 2019-06-06 2023-02-14 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
US11555190B2 (en) 2020-03-19 2023-01-17 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
KR20220161378A (ko) 2020-03-27 2022-12-06 어비디티 바이오사이언시스 인크. 근이영양증의 치료용 조성물 및 방법
US20230416786A1 (en) 2020-11-30 2023-12-28 Cellectis Sa Use of aminoquinoline compounds for higher gene integration
WO2023043953A1 (en) 2021-09-16 2023-03-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816893A (en) * 1957-12-17 Improvements in or relating to
US2901484A (en) * 1957-03-04 1959-08-25 Abbott Lab Bis-quinoliniums
US5510356A (en) * 1991-10-03 1996-04-23 University Of Nebraska Board Of Regents Bisquinolines and processes for their production and use to treat malaria

Also Published As

Publication number Publication date
IL114099A (en) 2000-02-29
MY115176A (en) 2003-04-30
WO1995035287A1 (en) 1995-12-28
CN1153513A (zh) 1997-07-02
CN1120156C (zh) 2003-09-03
AU2736995A (en) 1996-01-15
ES2204956T3 (es) 2004-05-01
CA2192203A1 (en) 1995-12-28
JPH10501540A (ja) 1998-02-10
AU691306B2 (en) 1998-05-14
ATE247642T1 (de) 2003-09-15
DE69531543T2 (de) 2004-06-24
EP0765313B1 (en) 2003-08-20
DK0765313T3 (da) 2003-12-08
MX9606382A (es) 1997-03-29
EP0765313A1 (en) 1997-04-02
IL114099A0 (en) 1995-10-31
DE69531543D1 (de) 2003-09-25
PT765313E (pt) 2003-11-28
NZ288223A (en) 1997-11-24
US5736557A (en) 1998-04-07

Similar Documents

Publication Publication Date Title
ZA954796B (en) Diamines
SG49153A1 (en) 5-HT4 receptor antagonists
HUT60464A (en) Process for producing n-phenylbenzamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient
DE69527839D1 (en) Tropan-2-aldoximderivate als neurotransmitter "reuptake" inhibitoren
GR3036606T3 (en) Pyrimidine or triazine carboxylic acid derivatives to be used as medicaments
HUT50325A (en) Process for producing bisphenylalkyl piperazine derivatives and pharmaceutical compositions comprising same as active ingredient
GB9305672D0 (en) Amide derivatives
HU9502068D0 (en) N-acyl pyrrolidines and drugs for the treatment or prevention of cholecystokinin and gastrin-related disorders
PH31388A (en) N-benzoylmethyl-piperidines.
HU9502067D0 (en) N-acyl pyrrolidines and drugs for the treatment or prevention of cholecystokinin and gastrin-related disorders
HU9500710D0 (en) Ureido-acetamide derivatives, preparation thereof and drugs containing same
FR2684992B1 (fr) Procede de preparation d'amino-2 nitro-7 benzothiazoles.
ZA954053B (en) Intermediate for preparing a pharmaceutically active compound
MX9705378A (es) Uso de los 3,4-difenil-cromanos para la fabricacion de una composicion farmaceutica para el tratamiento o profilaxis de la obesidad.